SP
SIH Partners Portfolio holdings
AUM
$1.05B
This Quarter Return
+0.17%
1 Year Return
+21.73%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$1.14B
AUM Growth
+$1.14B
(-20%)
Cap. Flow
-$258M
Cap. Flow
% of AUM
-22.66%
Top 10 Holdings %
Top 10 Hldgs %
64.91%
Holding
282
New
168
Increased
28
Reduced
29
Closed
25
Top Buys
| 1 |
iShares MSCI Emerging Markets ETF
EEM
|
$124M |
| 2 |
Stellantis
STLA
|
$33.7M |
| 3 |
KraneShares CSI China Internet ETF
KWEB
|
$33.3M |
| 4 |
NetEase
NTES
|
$28.6M |
| 5 |
iShares China Large-Cap ETF
FXI
|
$27.1M |
Top Sells
| 1 |
SPDR S&P 500 ETF Trust
SPY
|
$263M |
| 2 |
iShares JPMorgan USD Emerging Markets Bond ETF
EMB
|
$115M |
| 3 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
$108M |
| 4 |
UBS Group
UBS
|
$92.8M |
| 5 |
Logitech
LOGI
|
$31.8M |
Sector Composition
| 1 | Consumer Discretionary | 37.33% |
| 2 | Financials | 13.28% |
| 3 | Healthcare | 13% |
| 4 | Communication Services | 4.43% |
| 5 | Materials | 4.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
201
Acadia Pharmaceuticals
ACAD
$4.34B
| $179K | 0.01% |
+10,756
| New | +$179K |
|
202
BW LPG
BWLP
$2.3B
| $176K | 0.01% |
16,197
+6,197
| +62% | +$67.4K |
|
203
Adaptive Biotechnologies
ADPT
$1.96B
| $164K | 0.01% |
+22,113
| New | +$164K |
|
204
Amneal Pharmaceuticals
AMRX
$3B
| $164K | 0.01% |
+19,536
| New | +$164K |
|
205
Amicus Therapeutics
FOLD
$2.43B
| $158K | 0.01% |
+19,364
| New | +$158K |
|
206
Weibo
WB
$2.77B
| $147K | 0.01% |
15,500
-4,700
| -23% | -$44.5K |
|
207
ImmunityBio
IBRX
$2.25B
| $139K | ﹤0.01% |
+46,017
| New | +$139K |
|
208
10x Genomics
TXG
$1.66B
| $117K | ﹤0.01% |
+13,401
| New | +$117K |
|
209
Pacific Biosciences
PACB
$384M
| $108K | ﹤0.01% |
+91,128
| New | +$108K |
|
210
MannKind Corp
MNKD
$1.76B
| $96.2K | ﹤0.01% |
+19,132
| New | +$96.2K |
|
211
Intellia Therapeutics
NTLA
$1.22B
| $95.3K | ﹤0.01% |
+13,406
| New | +$95.3K |
|
212
BioCryst Pharmaceuticals
BCRX
$1.74B
| $94.8K | ﹤0.01% |
+12,639
| New | +$94.8K |
|
213
Lufax Holding
LU
$2.69B
| $81.4K | ﹤0.01% |
27,400
| – | – |
|
214
Uranium Energy
UEC
$4.86B
| $75.7K | ﹤0.01% |
+15,840
| New | +$75.7K |
|
215
Absci
ABSI
$351M
| $74.9K | ﹤0.01% |
+29,836
| New | +$74.9K |
|
216
Personalis
PSNL
$427M
| $70.1K | ﹤0.01% |
+19,966
| New | +$70.1K |
|
217
NexGen Energy
NXE
$4.38B
| $68.8K | ﹤0.01% |
+15,313
| New | +$68.8K |
|
218
Iovance Biotherapeutics
IOVA
$792M
| $68.7K | ﹤0.01% |
+20,637
| New | +$68.7K |
|
219
Ardelyx
ARDX
$1.55B
| $66.3K | ﹤0.01% |
+13,497
| New | +$66.3K |
|
220
Geron
GERN
$944M
| $63.4K | ﹤0.01% |
+39,868
| New | +$63.4K |
|
|
NGD
221
New Gold Inc
NGD
$4.83B
| $51.6K | ﹤0.01% |
13,895
+3,159
| +29% | +$11.7K |
|
222
Denison Mines
DNN
$2.04B
| $46.6K | ﹤0.01% |
+35,873
| New | +$46.6K |
|
223
Arbutus Biopharma
ABUS
$742M
| $43K | ﹤0.01% |
+12,318
| New | +$43K |
|
224
CureVac
CVAC
$1.21B
| $40.2K | ﹤0.01% |
+14,507
| New | +$40.2K |
|
225
AbCellera Biologics
ABCL
$1.21B
| $38.3K | ﹤0.01% |
+17,163
| New | +$38.3K |
|